OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
Bénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
RMD Open (2019) Vol. 5, Iss. 1, pp. e000763-e000763
Open Access | Times Cited: 34
Bénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
RMD Open (2019) Vol. 5, Iss. 1, pp. e000763-e000763
Open Access | Times Cited: 34
Showing 1-25 of 34 citing articles:
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 2, pp. 281-317
Open Access | Times Cited: 144
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 2, pp. 281-317
Open Access | Times Cited: 144
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 425-442
Open Access | Times Cited: 84
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 425-442
Open Access | Times Cited: 84
The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations
Jérôme Avouac, Hafid Ait‐Oufella, Caroline Habauzit, et al.
Rheumatology and Therapy (2025)
Open Access | Times Cited: 1
Jérôme Avouac, Hafid Ait‐Oufella, Caroline Habauzit, et al.
Rheumatology and Therapy (2025)
Open Access | Times Cited: 1
Inflammation and Heart Failure: Searching for the Enemy—Reaching the Entelechy
Ioannis Paraskevaidis, Dimitrios Farmakis, Georgios Papingiotis, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 1, pp. 19-19
Open Access | Times Cited: 19
Ioannis Paraskevaidis, Dimitrios Farmakis, Georgios Papingiotis, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 1, pp. 19-19
Open Access | Times Cited: 19
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
Laura Pina Vegas, Philippe Le Corvoisier, Laëtitia Penso, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 4, pp. 1589-1599
Open Access | Times Cited: 39
Laura Pina Vegas, Philippe Le Corvoisier, Laëtitia Penso, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 4, pp. 1589-1599
Open Access | Times Cited: 39
Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 6, pp. 583-609
Open Access | Times Cited: 23
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 6, pp. 583-609
Open Access | Times Cited: 23
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Kim Papp, Richard B. Warren, Lawrence Green, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 9, pp. e542-e552
Closed Access | Times Cited: 13
Kim Papp, Richard B. Warren, Lawrence Green, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 9, pp. e542-e552
Closed Access | Times Cited: 13
Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials
Wenhui Xie, Shiyu Xiao, Yanrong Huang, et al.
Therapeutic Advances in Musculoskeletal Disease (2019) Vol. 11
Open Access | Times Cited: 36
Wenhui Xie, Shiyu Xiao, Yanrong Huang, et al.
Therapeutic Advances in Musculoskeletal Disease (2019) Vol. 11
Open Access | Times Cited: 36
Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results
Timea Magdolna Szabo, Attila Frigy, E Nagy
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 13053-13053
Open Access | Times Cited: 24
Timea Magdolna Szabo, Attila Frigy, E Nagy
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 13053-13053
Open Access | Times Cited: 24
Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
Hong Ki Min, Se Hee Kim, Hae‐Rim Kim, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13913-13913
Open Access | Times Cited: 18
Hong Ki Min, Se Hee Kim, Hae‐Rim Kim, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13913-13913
Open Access | Times Cited: 18
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Laura Mateu Arrom, L. Puig
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 363-379
Closed Access | Times Cited: 3
Laura Mateu Arrom, L. Puig
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 363-379
Closed Access | Times Cited: 3
Multimorbidity and comorbidity in psoriatic arthritis – a perspective
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 10, pp. 963-972
Closed Access | Times Cited: 26
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 10, pp. 963-972
Closed Access | Times Cited: 26
The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni, Jiayi Zheng, Jimmy Varghese, et al.
Cureus (2024)
Open Access | Times Cited: 2
Ruoning Ni, Jiayi Zheng, Jimmy Varghese, et al.
Cureus (2024)
Open Access | Times Cited: 2
A systematic literature review of randomised controlled trials evaluating colchicine for cardiovascular prevention: There is an elephant in the room
Alessia Alunno, Francesco Carubbi, C. Martini, et al.
European Journal of Internal Medicine (2024) Vol. 125, pp. 44-50
Closed Access | Times Cited: 2
Alessia Alunno, Francesco Carubbi, C. Martini, et al.
European Journal of Internal Medicine (2024) Vol. 125, pp. 44-50
Closed Access | Times Cited: 2
The management of cardiovascular risk in psoriatic disease: A bridge over troubled water
Alessia Alunno, Francesco Carubbi, Javier Rodríguez‐Carrio, et al.
Seminars in Arthritis and Rheumatism (2024) Vol. 65, pp. 152389-152389
Open Access | Times Cited: 2
Alessia Alunno, Francesco Carubbi, Javier Rodríguez‐Carrio, et al.
Seminars in Arthritis and Rheumatism (2024) Vol. 65, pp. 152389-152389
Open Access | Times Cited: 2
Psoriasis management tree based on comorbidity
S. Abu Amara, Anusha Pasumarthi, Neil Parikh, et al.
International Journal of Dermatology (2024)
Closed Access | Times Cited: 2
S. Abu Amara, Anusha Pasumarthi, Neil Parikh, et al.
International Journal of Dermatology (2024)
Closed Access | Times Cited: 2
Cardiovascular risk according to biological agent exposure in patients with ankylosing spondylitis: a nationwide population-based study
Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, et al.
Clinical Rheumatology (2024) Vol. 44, Iss. 1, pp. 257-266
Closed Access | Times Cited: 2
Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, et al.
Clinical Rheumatology (2024) Vol. 44, Iss. 1, pp. 257-266
Closed Access | Times Cited: 2
Effect of disease modifying anti-rheumatic drugs on major cardiovascular events: a meta-analysis of randomized controlled trials
Shivshankar Thanigaimani, James Phie, Smriti M. Krishna, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 11
Shivshankar Thanigaimani, James Phie, Smriti M. Krishna, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 11
John Shi, Wei‐Yuan Chuang, Lai‐Shan Tam
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 11
Closed Access | Times Cited: 1
Managing psoriatic arthritis in different clinical scenarios
Rubén Queiró, Marta Loredo, Ignacio Braña, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 12, pp. 1469-1484
Closed Access | Times Cited: 3
Rubén Queiró, Marta Loredo, Ignacio Braña, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 12, pp. 1469-1484
Closed Access | Times Cited: 3
Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives
Eirini Kapniari, Prokopios Papadimitriou, Μaria Dalamaga, et al.
Current Vascular Pharmacology (2020) Vol. 18, Iss. 6, pp. 592-609
Closed Access | Times Cited: 8
Eirini Kapniari, Prokopios Papadimitriou, Μaria Dalamaga, et al.
Current Vascular Pharmacology (2020) Vol. 18, Iss. 6, pp. 592-609
Closed Access | Times Cited: 8
Commentary: Systemic effects of IL-17 in inflammatory arthritis
Pietro Enea Lazzerini, Franco Laghi‐Pasini, Mohamed Boutjdir, et al.
Frontiers in Cardiovascular Medicine (2019) Vol. 6
Open Access | Times Cited: 6
Pietro Enea Lazzerini, Franco Laghi‐Pasini, Mohamed Boutjdir, et al.
Frontiers in Cardiovascular Medicine (2019) Vol. 6
Open Access | Times Cited: 6
Biologics and Psoriasis: Treatment Selection with a Focus on Patient Comorbidities
Eduardo Michelen-Gómez, Zelma C. Chiesa Fuxench
Journal of Dermatology for Physician Assistants (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Eduardo Michelen-Gómez, Zelma C. Chiesa Fuxench
Journal of Dermatology for Physician Assistants (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice
Sneha Patel, Anand Kumthekar
Rheumatology and Therapy (2021) Vol. 9, Iss. 1, pp. 49-71
Open Access | Times Cited: 5
Sneha Patel, Anand Kumthekar
Rheumatology and Therapy (2021) Vol. 9, Iss. 1, pp. 49-71
Open Access | Times Cited: 5
